2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-N7395
    Cyclic ADP-​ribose 119340-53-3
    Cyclic ADP-ribose (cADPR) is a potent second messenger for calcium mobilization that is synthesized from NAD+ by an ADP-ribosyl cyclase. Cyclic ADP-ribose increases cytosolic calcium mainly by Ryanodine receptor-mediated release from endoplasmic reticulum and also by extracellular influx through the opening of TRPM2 channels.
    Cyclic ADP-​ribose
  • HY-N7676
    Marein 535-96-6 99.71%
    Marein has the neuroprotective effect due to a reduction of damage to mitochondria function and activation of the AMPK signal pathway. Marein improves insulin resistance induced by high glucose in HepG2 cells through CaMKK/AMPK/GLUT1 to promote glucose uptake, through IRS/Akt/GSK-3β to increase glycogen synthesis, and through Akt/FoxO1 to decrease gluconeogenesis. Marein is a HDAC inhibitor with an IC50 of 100 μM. Marein has beneficial antioxidative, antihypertensive, antihyperlipidemic and antidiabetic effects.
    Marein
  • HY-P1012
    [Sar9,Met(O2)11]-Substance P 110880-55-2 99.60%
    [Sar9,Met(O2)11]-Substance P is a tachykinin NK1 receptor selective agonist.
    [Sar9,Met(O2)11]-Substance P
  • HY-P1135
    M1145 1172089-00-7 99.60%
    M1145, a chimeric peptide, is a selective galanin receptor type 2 (GAL2) agonist, with a Ki of 6.55 nM. M1145 shows more than 90-fold higher affinity for GAL2 over GAL1 (Ki=587 nM) and a 76-fold higher affinity over GalR3 (Ki=497 nM). M1145 has an additive effect on the signal transduction of galanin.
    M1145
  • HY-P1349
    Orexin B, rat, mouse 202801-92-1
    Orexin B, rat, mouse (Rat orexin B) is an endogenous agonist at Orexin receptor with Kis of 420 and 36 nM for OX1 and OX2, respectively.
    Orexin B, rat, mouse
  • HY-P1422
    Spadin 1270083-24-3 99.08%
    Spadin, a natural peptide derived from a propeptide released in blood, is a potent TREK-1 channel blocker with IC50 value of 10 nM. Spadin enhances dorsal raphe nucleus 5-HT neurotransmission in mice and induces hippocampal CREB activation and neurogenesis. Spadin can be used for antidepressant research.
    Spadin
  • HY-P1529
    Thyrotropin-Releasing Hormone (TRH), Free Acid 24769-58-2 99.44%
    Thyrotropin-Releasing Hormone (TRH), Free Acid (TRH-OH) is a physiological metabolite of Thyrotropin-Releasing Hormone.
    Thyrotropin-Releasing Hormone (TRH), Free Acid
  • HY-P2727
    Chondroitinase ABC 9024-13-9
    Chondroitinase ABC (ChABC) is an enzyme that degrades glycosaminoglycan side-chains of chondroitin sulfate (CS-GAG) from the chondroitin sulfate proteoglycan (CSPG) core protein. Chondroitinase ABC facilitates reinnervation by degrading CS-GAGs around motoneurons. Chondroitinase ABC has the potential for the research of spinal injury.
    Chondroitinase ABC
  • HY-P3538
    Corticotropin-releasing factor (Sheep) 9015-71-8 99.67%
    Corticotropin-releasing factor (CRH) is a peptide hormone involved in stress responses. Corticotropin-releasing factor (CRF) is a major regulatory peptide in the hypothalamic-pituitary-adrenal (HPA) axis under stress conditions. Corticotropin-releasing factor (CRH) can be used for the research of neuroendocrine and anxiety-like behaviors.
    Corticotropin-releasing factor (Sheep)
  • HY-P4154
    Bevonescein 2276787-79-0 99.97%
    Bevonescein (ALM-488) is a novel, intravenously-administrated fluorescein-conjugated peptide that binds nerve-associated connective tissue, labels peripheral nerves under real-time fluorescence imaging (FL) in living mice and human ex vivo nerve tissue. Bevonescein is a peptide-linked tracer which fluorescently labeled both intact and degenerated nerves.
    Bevonescein
  • HY-Y0198
    2,6-Diaminopyridine 141-86-6 ≥98.0%
    2,6-Diaminopyridine is an intermediate and coupling agent for hair dyes. 2,6-Diaminopyridine participates in organic synthesis reactions such as N-methylation and can bind metal ions by forming macrocyclic ligands through condensation with aldehydes. 2,6-Diaminopyridine can be used to synthesize the analgesic phenazopyridine hydrochloride (HY-B0985).
    2,6-Diaminopyridine
  • HY-Y1683
    DL-Menthol 89-78-1 ≥98.0%
    DL-Menthol (Racementhol) is an orally active, GABAaR positive allosteric modulator and UDP-glucuronosyltransferase (UGT) inhibitor that can cross the blood-brain barrier. DL-Menthol binds to GABAAR and exhibits an allosteric activation effect, enhancing GABA-mediated chloride influx and inhibiting neuronal excitability. DL-Menthol can induce surgical anesthesia in fish and inhibit the metabolic detoxification of tobacco carcinogens by human liver and intestinal UGT enzymes, resulting in reduced NNAL-N-Gluc production.
    DL-Menthol
  • HY-100080
    A-887826 1266212-81-0 99.10%
    A-887826 is a potent, selective, oral bioavailable and voltage-dependent Na(v)1.8 sodium channel blocker with an IC50 of 11 nM . A-887826 attenuates neuropathic tactile allodynia in vivo.
    A-887826
  • HY-100182
    BACE1-IN-1 1310347-50-2 98.72%
    BACE1-IN-1 is a potent and highly brain penetrant BACE1 inhibitor with IC50s of 32 and 47 nM for human BACE1 and BACE2, respectively.
    BACE1-IN-1
  • HY-100769
    Hypidone hydrochloride 1339058-04-6 99.73%
    Hypidone hydrochloride (YL0919) is an orally active antidepressant agent with dual activity as a highly seletive 5-HT uptake blocker and an effective 5-HT1A receptor agonist (Ki=0.19 nM). Hypidone hydrochloride inhibits the uptake of [3H]-5-HT into rat cerebral cortical synaptosomes and HEK293 cells with IC50s of 1.78 nM and 1.93 nM, respectively. Hypidone hydrochloride shows remarkable antidepressant effects in animal models and has the poential for the investigation of depressive disorder.
    Hypidone hydrochloride
  • HY-101222
    SB-203186 hydrochloride 207572-69-8 99.94%
    SB-203186 hydrochloride is a potent, selective and competitive 5-HT4 antagonist. SB-203186 hydrochloride antagonizes the 5-HT4 receptor-mediated relaxations of the carbachol-contracted rat isolated oesophagus against 5-HT with pKB values of 10.9 (rat oesophagus), 9.5 (guinea-pig ileum), and 9.0 (human colon) respectively.
    SB-203186 hydrochloride
  • HY-101358
    8-M-PDOT 134865-70-6 ≥99.0%
    8-M-PDOT (AH-002) is a selective melatonin MT2 receptor agonist. 8-M-PDOT is 5.2-fold selective for MT2 over MT1 receptors. 8-M-PDOT binds human recombinant MT2 and MT2 receptors with pKi values of 8.23 and 8.95 respectively. 8-M-PDOT has anxiolytic-like activity.
    8-M-PDOT
  • HY-101858
    BQCA 338747-41-4 98.03%
    BQCA a highly selective allosteric modulator of the M1 mAChR.
    BQCA
  • HY-103099
    SB-399885 hydrochloride 402713-81-9 98.33%
    SB-399885 hydrochloride is a 5-HT6 receptor antagonist.
    SB-399885 hydrochloride
  • HY-103142
    AS19 1000578-26-6 ≥99.0%
    AS19 is a potent, selective 5-HT7 receptor agonist with an IC50 value of 0.83 nM and a Ki of 0.6 nM. AS19 is selective for 5-HT7 over 5-HT1A, 5-HT1B, 5-HT1D, and 5-HT5A receptors (Kis = 89.7 nM, 490 nM, 6.6 nM and 98.5 nM, respectively). AS19 enhances memory consolidation and reverses Scopolamine- or Dizocilpine-induced amnesia.
    AS19
Cat. No. Product Name / Synonyms Application Reactivity